{
	"@context": {
		"rdf": "http://www.w3.org/1999/02/22-rdf-syntax-ns#",
		"dct": "http://purl.org/dc/terms/",
		"owl": "http://www.w3.org/2002/07/owl#",
		"xsd": "http://www.w3.org/2001/XMLSchema#",
		"rdfs": "http://www.w3.org/2000/01/rdf-schema#",
		"@vocab": "http://ld.nice.org.uk/ns/bnf#",
		"bnf": "http://ld.nice.org.uk/ns/bnf/",
		"nicebnf": "http://ld.nice.org.uk/ns/bnf#",
		"route": "http://ld.nice.org.uk/ns/bnf/Route#",
		"patientGroup": "http://ld.nice.org.uk/ns/bnf/PatientGroup#",
		"indication": "http://ld.nice.org.uk/ns/bnf/Indication#",
		"sideEffect": "http://ld.nice.org.uk/ns/bnf/SideEffect#",
		"classification": "http://ld.nice.org.uk/ns/bnf/Classification#",
		"isLinkedFrom": {
			"@container": "@set"
		},
		"hasInteraction": {
			"@container": "@set"
		},
		"hasMessage": {
			"@container": "@set"
		},
		"hasInteractionList": {
			"@container": "@set"
		},
		"isInteractionListOf": {
			"@container": "@set"
		}
	},
	"@graph": [
		{
			"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2",
			"@type": "InteractionList",
			"hasInteraction": [
				{
					"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977878",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977878_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"ivacaftor\" outputclass=\"int-heading-drug\">Ivacaftor</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"afatinib\" outputclass=\"int-drug\">afatinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises separate administration by 12 hours</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Ivacaftor   is predicted to   increase   the exposure to   afatinib .  Manufacturer advises separate administration by 12 hours .    \n\n"
						}
					],
					"hasOrder": "1",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Afatinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977879",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977879_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"ivacaftor\" outputclass=\"int-heading-drug\">Ivacaftor</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"aliskiren\" outputclass=\"int-drug\">aliskiren</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Ivacaftor   is predicted to   increase   the exposure to   aliskiren .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "2",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Aliskiren</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977880",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977880_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"apalutamide\" outputclass=\"int-drug\">Apalutamide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ivacaftor\" outputclass=\"int-heading-drug\">ivacaftor</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Apalutamide   is predicted to   decrease   the exposure to   ivacaftor .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "3",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Apalutamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977881",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977881_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"aprepitant\" outputclass=\"int-drug\">Aprepitant</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ivacaftor\" outputclass=\"int-heading-drug\">ivacaftor</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust dose with moderate CYP3A4 inhibitors, see <xref format=\"dita\" href=\"drug/ivacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP33421\">ivacaftor</xref>, <xref format=\"dita\" href=\"drug/tezacaftor-with-ivacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP218356\">tezacaftor with ivacaftor</xref>, and <xref format=\"dita\" href=\"drug/tezacaftor-with-ivacaftor-and-elexacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP221286\">tezacaftor with ivacaftor and elexacaftor</xref></ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Aprepitant   is predicted to   increase   the exposure to   ivacaftor .  Manufacturer advises adjust dose with moderate CYP3A4 inhibitors, see  ivacaftor ,  tezacaftor with ivacaftor , and  tezacaftor with ivacaftor and elexacaftor .    \n\n"
						}
					],
					"hasOrder": "4",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Aprepitant</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977882",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977882_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"atazanavir\" outputclass=\"int-drug\">Atazanavir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ivacaftor\" outputclass=\"int-heading-drug\">ivacaftor</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust dose with potent CYP3A4 inhibitors, see <xref format=\"dita\" href=\"drug/ivacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP33421\">ivacaftor</xref>, <xref format=\"dita\" href=\"drug/lumacaftor-with-ivacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP202230\">lumacaftor with ivacaftor</xref>, <xref format=\"dita\" href=\"drug/tezacaftor-with-ivacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP218356\">tezacaftor with ivacaftor</xref>, and <xref format=\"dita\" href=\"drug/tezacaftor-with-ivacaftor-and-elexacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP221286\">tezacaftor with ivacaftor and elexacaftor</xref></ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Atazanavir   is predicted to   increase   the exposure to   ivacaftor .  Manufacturer advises adjust dose with potent CYP3A4 inhibitors, see  ivacaftor ,  lumacaftor with ivacaftor ,  tezacaftor with ivacaftor , and  tezacaftor with ivacaftor and elexacaftor .    \n\n"
						}
					],
					"hasOrder": "5",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Atazanavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977883",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977883_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"ivacaftor\" outputclass=\"int-heading-drug\">Ivacaftor</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"berotralstat\" outputclass=\"int-drug\">berotralstat</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Ivacaftor   is predicted to   increase   the exposure to   berotralstat .  Manufacturer advises monitor .    \n\n"
						}
					],
					"hasOrder": "6",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Berotralstat</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977884",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977884_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"ivacaftor\" outputclass=\"int-heading-drug\">Ivacaftor</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"bictegravir\" outputclass=\"int-drug\">bictegravir</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Ivacaftor   is predicted to   increase   the exposure to   bictegravir .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "7",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bictegravir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977885",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977885_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"bosentan\" outputclass=\"int-drug\">Bosentan</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ivacaftor\" outputclass=\"int-heading-drug\">ivacaftor</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Bosentan   is predicted to   decrease   the exposure to   ivacaftor .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "8",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bosentan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977886",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977886_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"carbamazepine\" outputclass=\"int-drug\">Carbamazepine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ivacaftor\" outputclass=\"int-heading-drug\">ivacaftor</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Carbamazepine   is predicted to   decrease   the exposure to   ivacaftor .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "9",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Carbamazepine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977887",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977887_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"cenobamate\" outputclass=\"int-drug\">Cenobamate</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ivacaftor\" outputclass=\"int-heading-drug\">ivacaftor</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Cenobamate   is predicted to   decrease   the exposure to   ivacaftor .  Manufacturer advises adjust dose .    \n\n"
						}
					],
					"hasOrder": "10",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cenobamate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977888",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977888_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"ivacaftor\" outputclass=\"int-heading-drug\">Ivacaftor</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ciclosporin\" outputclass=\"int-drug\">ciclosporin</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Ivacaftor   is predicted to   increase   the exposure to   ciclosporin .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "11",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ciclosporin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977889",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977889_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"clarithromycin\" outputclass=\"int-drug\">Clarithromycin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ivacaftor\" outputclass=\"int-heading-drug\">ivacaftor</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust dose with potent CYP3A4 inhibitors, see <xref format=\"dita\" href=\"drug/ivacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP33421\">ivacaftor</xref>, <xref format=\"dita\" href=\"drug/lumacaftor-with-ivacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP202230\">lumacaftor with ivacaftor</xref>, <xref format=\"dita\" href=\"drug/tezacaftor-with-ivacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP218356\">tezacaftor with ivacaftor</xref>, and <xref format=\"dita\" href=\"drug/tezacaftor-with-ivacaftor-and-elexacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP221286\">tezacaftor with ivacaftor and elexacaftor</xref></ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Clarithromycin   is predicted to   increase   the exposure to   ivacaftor .  Manufacturer advises adjust dose with potent CYP3A4 inhibitors, see  ivacaftor ,  lumacaftor with ivacaftor ,  tezacaftor with ivacaftor , and  tezacaftor with ivacaftor and elexacaftor .    \n\n"
						}
					],
					"hasOrder": "12",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clarithromycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977890",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977890_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"cobicistat\" outputclass=\"int-drug\">Cobicistat</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ivacaftor\" outputclass=\"int-heading-drug\">ivacaftor</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust dose with potent CYP3A4 inhibitors, see <xref format=\"dita\" href=\"drug/ivacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP33421\">ivacaftor</xref>, <xref format=\"dita\" href=\"drug/lumacaftor-with-ivacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP202230\">lumacaftor with ivacaftor</xref>, <xref format=\"dita\" href=\"drug/tezacaftor-with-ivacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP218356\">tezacaftor with ivacaftor</xref>, and <xref format=\"dita\" href=\"drug/tezacaftor-with-ivacaftor-and-elexacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP221286\">tezacaftor with ivacaftor and elexacaftor</xref></ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Cobicistat   is predicted to   increase   the exposure to   ivacaftor .  Manufacturer advises adjust dose with potent CYP3A4 inhibitors, see  ivacaftor ,  lumacaftor with ivacaftor ,  tezacaftor with ivacaftor , and  tezacaftor with ivacaftor and elexacaftor .    \n\n"
						}
					],
					"hasOrder": "13",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cobicistat</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977891",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977891_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"ivacaftor\" outputclass=\"int-heading-drug\">Ivacaftor</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"colchicine\" outputclass=\"int-drug\">colchicine</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Ivacaftor   is predicted to   increase   the exposure to   colchicine .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "14",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Colchicine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977892",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977892_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"crizotinib\" outputclass=\"int-drug\">Crizotinib</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ivacaftor\" outputclass=\"int-heading-drug\">ivacaftor</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust dose with moderate CYP3A4 inhibitors, see <xref format=\"dita\" href=\"drug/ivacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP33421\">ivacaftor</xref>, <xref format=\"dita\" href=\"drug/tezacaftor-with-ivacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP218356\">tezacaftor with ivacaftor</xref>, and <xref format=\"dita\" href=\"drug/tezacaftor-with-ivacaftor-and-elexacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP221286\">tezacaftor with ivacaftor and elexacaftor</xref></ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Crizotinib   is predicted to   increase   the exposure to   ivacaftor .  Manufacturer advises adjust dose with moderate CYP3A4 inhibitors, see  ivacaftor ,  tezacaftor with ivacaftor , and  tezacaftor with ivacaftor and elexacaftor .    \n\n"
						}
					],
					"hasOrder": "15",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Crizotinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977893",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977893_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"ivacaftor\" outputclass=\"int-heading-drug\">Ivacaftor</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dabigatran\" outputclass=\"int-drug\">dabigatran</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Ivacaftor   is predicted to   increase   the exposure to   dabigatran .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "16",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dabigatran</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977894",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977894_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"dabrafenib\" outputclass=\"int-drug\">Dabrafenib</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ivacaftor\" outputclass=\"int-heading-drug\">ivacaftor</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Dabrafenib   is predicted to   decrease   the exposure to   ivacaftor .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "17",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dabrafenib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977895",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977895_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"darunavir\" outputclass=\"int-drug\">Darunavir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ivacaftor\" outputclass=\"int-heading-drug\">ivacaftor</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust dose with potent CYP3A4 inhibitors, see <xref format=\"dita\" href=\"drug/ivacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP33421\">ivacaftor</xref>, <xref format=\"dita\" href=\"drug/lumacaftor-with-ivacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP202230\">lumacaftor with ivacaftor</xref>, <xref format=\"dita\" href=\"drug/tezacaftor-with-ivacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP218356\">tezacaftor with ivacaftor</xref>, and <xref format=\"dita\" href=\"drug/tezacaftor-with-ivacaftor-and-elexacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP221286\">tezacaftor with ivacaftor and elexacaftor</xref></ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Darunavir   is predicted to   increase   the exposure to   ivacaftor .  Manufacturer advises adjust dose with potent CYP3A4 inhibitors, see  ivacaftor ,  lumacaftor with ivacaftor ,  tezacaftor with ivacaftor , and  tezacaftor with ivacaftor and elexacaftor .    \n\n"
						}
					],
					"hasOrder": "18",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Darunavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977896",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977896_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"ivacaftor\" outputclass=\"int-heading-drug\">Ivacaftor</ph> <ph outputclass=\"int-magnitude\">slightly</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"digoxin\" outputclass=\"int-drug\">digoxin</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Ivacaftor   slightly   increases   the exposure to   digoxin .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "19",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Digoxin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977897",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977897_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"diltiazem\" outputclass=\"int-drug\">Diltiazem</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ivacaftor\" outputclass=\"int-heading-drug\">ivacaftor</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust dose with moderate CYP3A4 inhibitors, see <xref format=\"dita\" href=\"drug/ivacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP33421\">ivacaftor</xref>, <xref format=\"dita\" href=\"drug/tezacaftor-with-ivacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP218356\">tezacaftor with ivacaftor</xref>, and <xref format=\"dita\" href=\"drug/tezacaftor-with-ivacaftor-and-elexacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP221286\">tezacaftor with ivacaftor and elexacaftor</xref></ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Diltiazem   is predicted to   increase   the exposure to   ivacaftor .  Manufacturer advises adjust dose with moderate CYP3A4 inhibitors, see  ivacaftor ,  tezacaftor with ivacaftor , and  tezacaftor with ivacaftor and elexacaftor .    \n\n"
						}
					],
					"hasOrder": "20",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Diltiazem</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977898",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977898_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Unknown\" outputclass=\"int-message\">\n  <ph otherprops=\"ivacaftor\" outputclass=\"int-heading-drug\">Ivacaftor</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"docetaxel\" outputclass=\"int-drug\">docetaxel</ph> <ph outputclass=\"int-substanceQualifier\">(oral)</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Unknown",
							"hasOrder": "1",
							"hasTextContent": "Ivacaftor   is predicted to   increase   the exposure to   docetaxel   (oral) .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "21",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Docetaxel</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977899",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977899_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ivacaftor\" outputclass=\"int-heading-drug\">ivacaftor</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust dose with moderate CYP3A4 inhibitors, see <xref format=\"dita\" href=\"drug/ivacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP33421\">ivacaftor</xref>, <xref format=\"dita\" href=\"drug/tezacaftor-with-ivacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP218356\">tezacaftor with ivacaftor</xref>, and <xref format=\"dita\" href=\"drug/tezacaftor-with-ivacaftor-and-elexacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP221286\">tezacaftor with ivacaftor and elexacaftor</xref></ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   ivacaftor .  Manufacturer advises adjust dose with moderate CYP3A4 inhibitors, see  ivacaftor ,  tezacaftor with ivacaftor , and  tezacaftor with ivacaftor and elexacaftor .    \n\n"
						}
					],
					"hasOrder": "22",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dronedarone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977900",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977900_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"ivacaftor\" outputclass=\"int-heading-drug\">Ivacaftor</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"edoxaban\" outputclass=\"int-drug\">edoxaban</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Ivacaftor   is predicted to   increase   the exposure to   edoxaban .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "23",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Edoxaban</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977901",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977901_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"efavirenz\" outputclass=\"int-drug\">Efavirenz</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ivacaftor\" outputclass=\"int-heading-drug\">ivacaftor</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Efavirenz   is predicted to   decrease   the exposure to   ivacaftor .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "24",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Efavirenz</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977902",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977902_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"enzalutamide\" outputclass=\"int-drug\">Enzalutamide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ivacaftor\" outputclass=\"int-heading-drug\">ivacaftor</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Enzalutamide   is predicted to   decrease   the exposure to   ivacaftor .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "25",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Enzalutamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977903",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977903_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"ivacaftor\" outputclass=\"int-heading-drug\">Ivacaftor</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"erlotinib\" outputclass=\"int-drug\">erlotinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Ivacaftor   is predicted to   increase   the exposure to   erlotinib .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "26",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Erlotinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977904",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977904_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"erythromycin\" outputclass=\"int-drug\">Erythromycin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ivacaftor\" outputclass=\"int-heading-drug\">ivacaftor</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust dose with moderate CYP3A4 inhibitors, see <xref format=\"dita\" href=\"drug/ivacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP33421\">ivacaftor</xref>, <xref format=\"dita\" href=\"drug/tezacaftor-with-ivacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP218356\">tezacaftor with ivacaftor</xref>, and <xref format=\"dita\" href=\"drug/tezacaftor-with-ivacaftor-and-elexacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP221286\">tezacaftor with ivacaftor and elexacaftor</xref></ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Erythromycin   is predicted to   increase   the exposure to   ivacaftor .  Manufacturer advises adjust dose with moderate CYP3A4 inhibitors, see  ivacaftor ,  tezacaftor with ivacaftor , and  tezacaftor with ivacaftor and elexacaftor .    \n\n"
						}
					],
					"hasOrder": "27",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Erythromycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977905",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977905_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"ivacaftor\" outputclass=\"int-heading-drug\">Ivacaftor</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"everolimus\" outputclass=\"int-drug\">everolimus</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Ivacaftor   is predicted to   increase   the exposure to   everolimus .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "28",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Everolimus</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977906",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977906_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"ivacaftor\" outputclass=\"int-heading-drug\">Ivacaftor</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"fexofenadine\" outputclass=\"int-drug\">fexofenadine</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Ivacaftor   is predicted to   increase   the exposure to   fexofenadine .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "29",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fexofenadine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977907",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977907_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"ivacaftor\" outputclass=\"int-heading-drug\">Ivacaftor</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"fidaxomicin\" outputclass=\"int-drug\">fidaxomicin</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Ivacaftor   is predicted to   increase   the exposure to   fidaxomicin .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "30",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fidaxomicin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977908",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977908_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"fluconazole\" outputclass=\"int-drug\">Fluconazole</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ivacaftor\" outputclass=\"int-heading-drug\">ivacaftor</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust dose with moderate CYP3A4 inhibitors, see <xref format=\"dita\" href=\"drug/ivacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP33421\">ivacaftor</xref>, <xref format=\"dita\" href=\"drug/tezacaftor-with-ivacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP218356\">tezacaftor with ivacaftor</xref>, and <xref format=\"dita\" href=\"drug/tezacaftor-with-ivacaftor-and-elexacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP221286\">tezacaftor with ivacaftor and elexacaftor</xref></ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Fluconazole   is predicted to   increase   the exposure to   ivacaftor .  Manufacturer advises adjust dose with moderate CYP3A4 inhibitors, see  ivacaftor ,  tezacaftor with ivacaftor , and  tezacaftor with ivacaftor and elexacaftor .    \n\n"
						}
					],
					"hasOrder": "31",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fluconazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977909",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977909_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fosamprenavir\" outputclass=\"int-drug\">Fosamprenavir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ivacaftor\" outputclass=\"int-heading-drug\">ivacaftor</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust dose with potent CYP3A4 inhibitors, see <xref format=\"dita\" href=\"drug/ivacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP33421\">ivacaftor</xref>, <xref format=\"dita\" href=\"drug/lumacaftor-with-ivacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP202230\">lumacaftor with ivacaftor</xref>, <xref format=\"dita\" href=\"drug/tezacaftor-with-ivacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP218356\">tezacaftor with ivacaftor</xref>, and <xref format=\"dita\" href=\"drug/tezacaftor-with-ivacaftor-and-elexacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP221286\">tezacaftor with ivacaftor and elexacaftor</xref></ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Fosamprenavir   is predicted to   increase   the exposure to   ivacaftor .  Manufacturer advises adjust dose with potent CYP3A4 inhibitors, see  ivacaftor ,  lumacaftor with ivacaftor ,  tezacaftor with ivacaftor , and  tezacaftor with ivacaftor and elexacaftor .    \n\n"
						}
					],
					"hasOrder": "32",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fosamprenavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977910",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977910_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fosphenytoin\" outputclass=\"int-drug\">Fosphenytoin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ivacaftor\" outputclass=\"int-heading-drug\">ivacaftor</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Fosphenytoin   is predicted to   decrease   the exposure to   ivacaftor .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "33",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fosphenytoin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977911",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977911_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"ivacaftor\" outputclass=\"int-heading-drug\">Ivacaftor</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"gilteritinib\" outputclass=\"int-drug\">gilteritinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Ivacaftor   is predicted to   increase   the exposure to   gilteritinib .  Manufacturer advises monitor .    \n\n"
						}
					],
					"hasOrder": "34",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Gilteritinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977912",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977912_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"grapefruit\" outputclass=\"int-drug\">Grapefruit</ph> <ph outputclass=\"int-substanceQualifier\">juice</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ivacaftor\" outputclass=\"int-heading-drug\">ivacaftor</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Grapefruit   juice   is predicted to   increase   the exposure to   ivacaftor .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "35",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Grapefruit</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977913",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977913_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"idelalisib\" outputclass=\"int-drug\">Idelalisib</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ivacaftor\" outputclass=\"int-heading-drug\">ivacaftor</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust dose with potent CYP3A4 inhibitors, see <xref format=\"dita\" href=\"drug/ivacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP33421\">ivacaftor</xref>, <xref format=\"dita\" href=\"drug/lumacaftor-with-ivacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP202230\">lumacaftor with ivacaftor</xref>, <xref format=\"dita\" href=\"drug/tezacaftor-with-ivacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP218356\">tezacaftor with ivacaftor</xref>, and <xref format=\"dita\" href=\"drug/tezacaftor-with-ivacaftor-and-elexacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP221286\">tezacaftor with ivacaftor and elexacaftor</xref></ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Idelalisib   is predicted to   increase   the exposure to   ivacaftor .  Manufacturer advises adjust dose with potent CYP3A4 inhibitors, see  ivacaftor ,  lumacaftor with ivacaftor ,  tezacaftor with ivacaftor , and  tezacaftor with ivacaftor and elexacaftor .    \n\n"
						}
					],
					"hasOrder": "36",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Idelalisib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977914",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977914_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"imatinib\" outputclass=\"int-drug\">Imatinib</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ivacaftor\" outputclass=\"int-heading-drug\">ivacaftor</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust dose with moderate CYP3A4 inhibitors, see <xref format=\"dita\" href=\"drug/ivacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP33421\">ivacaftor</xref>, <xref format=\"dita\" href=\"drug/tezacaftor-with-ivacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP218356\">tezacaftor with ivacaftor</xref>, and <xref format=\"dita\" href=\"drug/tezacaftor-with-ivacaftor-and-elexacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP221286\">tezacaftor with ivacaftor and elexacaftor</xref></ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Imatinib   is predicted to   increase   the exposure to   ivacaftor .  Manufacturer advises adjust dose with moderate CYP3A4 inhibitors, see  ivacaftor ,  tezacaftor with ivacaftor , and  tezacaftor with ivacaftor and elexacaftor .    \n\n"
						}
					],
					"hasOrder": "37",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Imatinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977915",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977915_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"isavuconazole\" outputclass=\"int-drug\">Isavuconazole</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ivacaftor\" outputclass=\"int-heading-drug\">ivacaftor</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust dose with moderate CYP3A4 inhibitors, see <xref format=\"dita\" href=\"drug/ivacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP33421\">ivacaftor</xref>, <xref format=\"dita\" href=\"drug/tezacaftor-with-ivacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP218356\">tezacaftor with ivacaftor</xref>, and <xref format=\"dita\" href=\"drug/tezacaftor-with-ivacaftor-and-elexacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP221286\">tezacaftor with ivacaftor and elexacaftor</xref></ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Isavuconazole   is predicted to   increase   the exposure to   ivacaftor .  Manufacturer advises adjust dose with moderate CYP3A4 inhibitors, see  ivacaftor ,  tezacaftor with ivacaftor , and  tezacaftor with ivacaftor and elexacaftor .    \n\n"
						}
					],
					"hasOrder": "38",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Isavuconazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977916",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977916_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"itraconazole\" outputclass=\"int-drug\">Itraconazole</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ivacaftor\" outputclass=\"int-heading-drug\">ivacaftor</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust dose with potent CYP3A4 inhibitors, see <xref format=\"dita\" href=\"drug/ivacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP33421\">ivacaftor</xref>, <xref format=\"dita\" href=\"drug/lumacaftor-with-ivacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP202230\">lumacaftor with ivacaftor</xref>, <xref format=\"dita\" href=\"drug/tezacaftor-with-ivacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP218356\">tezacaftor with ivacaftor</xref>, and <xref format=\"dita\" href=\"drug/tezacaftor-with-ivacaftor-and-elexacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP221286\">tezacaftor with ivacaftor and elexacaftor</xref></ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Itraconazole   is predicted to   increase   the exposure to   ivacaftor .  Manufacturer advises adjust dose with potent CYP3A4 inhibitors, see  ivacaftor ,  lumacaftor with ivacaftor ,  tezacaftor with ivacaftor , and  tezacaftor with ivacaftor and elexacaftor .    \n\n"
						}
					],
					"hasOrder": "39",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Itraconazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977917",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977917_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"ketoconazole\" outputclass=\"int-drug\">Ketoconazole</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ivacaftor\" outputclass=\"int-heading-drug\">ivacaftor</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust dose with potent CYP3A4 inhibitors, see <xref format=\"dita\" href=\"drug/ivacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP33421\">ivacaftor</xref>, <xref format=\"dita\" href=\"drug/lumacaftor-with-ivacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP202230\">lumacaftor with ivacaftor</xref>, <xref format=\"dita\" href=\"drug/tezacaftor-with-ivacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP218356\">tezacaftor with ivacaftor</xref>, and <xref format=\"dita\" href=\"drug/tezacaftor-with-ivacaftor-and-elexacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP221286\">tezacaftor with ivacaftor and elexacaftor</xref></ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Ketoconazole   is predicted to   increase   the exposure to   ivacaftor .  Manufacturer advises adjust dose with potent CYP3A4 inhibitors, see  ivacaftor ,  lumacaftor with ivacaftor ,  tezacaftor with ivacaftor , and  tezacaftor with ivacaftor and elexacaftor .    \n\n"
						}
					],
					"hasOrder": "40",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ketoconazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977918",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977918_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"letermovir\" outputclass=\"int-drug\">Letermovir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ivacaftor\" outputclass=\"int-heading-drug\">ivacaftor</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust dose with moderate CYP3A4 inhibitors, see <xref format=\"dita\" href=\"drug/ivacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP33421\">ivacaftor</xref>, <xref format=\"dita\" href=\"drug/tezacaftor-with-ivacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP218356\">tezacaftor with ivacaftor</xref>, and <xref format=\"dita\" href=\"drug/tezacaftor-with-ivacaftor-and-elexacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP221286\">tezacaftor with ivacaftor and elexacaftor</xref></ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Letermovir   is predicted to   increase   the exposure to   ivacaftor .  Manufacturer advises adjust dose with moderate CYP3A4 inhibitors, see  ivacaftor ,  tezacaftor with ivacaftor , and  tezacaftor with ivacaftor and elexacaftor .    \n\n"
						}
					],
					"hasOrder": "41",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Letermovir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977919",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977919_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"ivacaftor\" outputclass=\"int-heading-drug\">Ivacaftor</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"lomitapide\" outputclass=\"int-drug\">lomitapide</ph>. <ph outputclass=\"int-action\">Manufacturer advises separate administration by 12 hours</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Ivacaftor   is predicted to   increase   the exposure to   lomitapide .  Manufacturer advises separate administration by 12 hours .    \n\n"
						}
					],
					"hasOrder": "42",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lomitapide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977920",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977920_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"ivacaftor\" outputclass=\"int-heading-drug\">Ivacaftor</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"loperamide\" outputclass=\"int-drug\">loperamide</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Ivacaftor   is predicted to   increase   the exposure to   loperamide .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "43",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Loperamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977921",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977921_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"lopinavir\" outputclass=\"int-drug\">Lopinavir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ivacaftor\" outputclass=\"int-heading-drug\">ivacaftor</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust dose with potent CYP3A4 inhibitors, see <xref format=\"dita\" href=\"drug/ivacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP33421\">ivacaftor</xref>, <xref format=\"dita\" href=\"drug/lumacaftor-with-ivacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP202230\">lumacaftor with ivacaftor</xref>, <xref format=\"dita\" href=\"drug/tezacaftor-with-ivacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP218356\">tezacaftor with ivacaftor</xref>, and <xref format=\"dita\" href=\"drug/tezacaftor-with-ivacaftor-and-elexacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP221286\">tezacaftor with ivacaftor and elexacaftor</xref></ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Lopinavir   is predicted to   increase   the exposure to   ivacaftor .  Manufacturer advises adjust dose with potent CYP3A4 inhibitors, see  ivacaftor ,  lumacaftor with ivacaftor ,  tezacaftor with ivacaftor , and  tezacaftor with ivacaftor and elexacaftor .    \n\n"
						}
					],
					"hasOrder": "44",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lopinavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977922",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977922_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"mitotane\" outputclass=\"int-drug\">Mitotane</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ivacaftor\" outputclass=\"int-heading-drug\">ivacaftor</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Mitotane   is predicted to   decrease   the exposure to   ivacaftor .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "45",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mitotane</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977923",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977923_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"netupitant\" outputclass=\"int-drug\">Netupitant</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ivacaftor\" outputclass=\"int-heading-drug\">ivacaftor</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust dose with moderate CYP3A4 inhibitors, see <xref format=\"dita\" href=\"drug/ivacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP33421\">ivacaftor</xref>, <xref format=\"dita\" href=\"drug/tezacaftor-with-ivacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP218356\">tezacaftor with ivacaftor</xref>, and <xref format=\"dita\" href=\"drug/tezacaftor-with-ivacaftor-and-elexacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP221286\">tezacaftor with ivacaftor and elexacaftor</xref></ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Netupitant   is predicted to   increase   the exposure to   ivacaftor .  Manufacturer advises adjust dose with moderate CYP3A4 inhibitors, see  ivacaftor ,  tezacaftor with ivacaftor , and  tezacaftor with ivacaftor and elexacaftor .    \n\n"
						}
					],
					"hasOrder": "46",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Netupitant</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977924",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977924_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"nevirapine\" outputclass=\"int-drug\">Nevirapine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ivacaftor\" outputclass=\"int-heading-drug\">ivacaftor</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Nevirapine   is predicted to   decrease   the exposure to   ivacaftor .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "47",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nevirapine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977925",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977925_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"nilotinib\" outputclass=\"int-drug\">Nilotinib</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ivacaftor\" outputclass=\"int-heading-drug\">ivacaftor</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust dose with moderate CYP3A4 inhibitors, see <xref format=\"dita\" href=\"drug/ivacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP33421\">ivacaftor</xref>, <xref format=\"dita\" href=\"drug/tezacaftor-with-ivacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP218356\">tezacaftor with ivacaftor</xref>, and <xref format=\"dita\" href=\"drug/tezacaftor-with-ivacaftor-and-elexacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP221286\">tezacaftor with ivacaftor and elexacaftor</xref></ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Nilotinib   is predicted to   increase   the exposure to   ivacaftor .  Manufacturer advises adjust dose with moderate CYP3A4 inhibitors, see  ivacaftor ,  tezacaftor with ivacaftor , and  tezacaftor with ivacaftor and elexacaftor .    \n\n"
						}
					],
					"hasOrder": "48",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nilotinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977926",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977926_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"ivacaftor\" outputclass=\"int-heading-drug\">Ivacaftor</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"nintedanib\" outputclass=\"int-drug\">nintedanib</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Ivacaftor   is predicted to   increase   the exposure to   nintedanib .  Manufacturer advises monitor .    \n\n"
						}
					],
					"hasOrder": "49",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nintedanib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977927",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977927_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Unknown\" outputclass=\"int-message\">\n  <ph otherprops=\"ivacaftor\" outputclass=\"int-heading-drug\">Ivacaftor</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"paclitaxel\" outputclass=\"int-drug\">paclitaxel</ph> <ph outputclass=\"int-substanceQualifier\">(oral)</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Unknown",
							"hasOrder": "1",
							"hasTextContent": "Ivacaftor   is predicted to   increase   the exposure to   paclitaxel   (oral) .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "50",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Paclitaxel</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977928",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977928_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"phenobarbital\" outputclass=\"int-drug\">Phenobarbital</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ivacaftor\" outputclass=\"int-heading-drug\">ivacaftor</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Phenobarbital   is predicted to   decrease   the exposure to   ivacaftor .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "51",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Phenobarbital</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977929",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977929_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"phenytoin\" outputclass=\"int-drug\">Phenytoin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ivacaftor\" outputclass=\"int-heading-drug\">ivacaftor</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Phenytoin   is predicted to   decrease   the exposure to   ivacaftor .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "52",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Phenytoin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977930",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977930_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"posaconazole\" outputclass=\"int-drug\">Posaconazole</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ivacaftor\" outputclass=\"int-heading-drug\">ivacaftor</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust dose with moderate CYP3A4 inhibitors, see <xref format=\"dita\" href=\"drug/ivacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP33421\">ivacaftor</xref>, <xref format=\"dita\" href=\"drug/tezacaftor-with-ivacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP218356\">tezacaftor with ivacaftor</xref>, and <xref format=\"dita\" href=\"drug/tezacaftor-with-ivacaftor-and-elexacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP221286\">tezacaftor with ivacaftor and elexacaftor</xref></ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Posaconazole   is predicted to   increase   the exposure to   ivacaftor .  Manufacturer advises adjust dose with moderate CYP3A4 inhibitors, see  ivacaftor ,  tezacaftor with ivacaftor , and  tezacaftor with ivacaftor and elexacaftor .    \n\n"
						}
					],
					"hasOrder": "53",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Posaconazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977931",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977931_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"primidone\" outputclass=\"int-drug\">Primidone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ivacaftor\" outputclass=\"int-heading-drug\">ivacaftor</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Primidone   is predicted to   decrease   the exposure to   ivacaftor .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "54",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Primidone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977932",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977932_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"ivacaftor\" outputclass=\"int-heading-drug\">Ivacaftor</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"relugolix\" outputclass=\"int-drug\">relugolix</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid or take relugolix first and separate administration by at least 6 hours</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Ivacaftor   is predicted to   increase   the exposure to   relugolix .  Manufacturer advises avoid or take relugolix first and separate administration by at least 6 hours .    \n\n"
						}
					],
					"hasOrder": "55",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Relugolix</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977933",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977933_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"rifampicin\" outputclass=\"int-drug\">Rifampicin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ivacaftor\" outputclass=\"int-heading-drug\">ivacaftor</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Rifampicin   is predicted to   decrease   the exposure to   ivacaftor .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "56",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rifampicin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977934",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977934_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"ritonavir\" outputclass=\"int-drug\">Ritonavir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ivacaftor\" outputclass=\"int-heading-drug\">ivacaftor</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust dose with potent CYP3A4 inhibitors, see <xref format=\"dita\" href=\"drug/ivacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP33421\">ivacaftor</xref>, <xref format=\"dita\" href=\"drug/lumacaftor-with-ivacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP202230\">lumacaftor with ivacaftor</xref>, <xref format=\"dita\" href=\"drug/tezacaftor-with-ivacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP218356\">tezacaftor with ivacaftor</xref>, and <xref format=\"dita\" href=\"drug/tezacaftor-with-ivacaftor-and-elexacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP221286\">tezacaftor with ivacaftor and elexacaftor</xref></ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Ritonavir   is predicted to   increase   the exposure to   ivacaftor .  Manufacturer advises adjust dose with potent CYP3A4 inhibitors, see  ivacaftor ,  lumacaftor with ivacaftor ,  tezacaftor with ivacaftor , and  tezacaftor with ivacaftor and elexacaftor .    \n\n"
						}
					],
					"hasOrder": "57",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ritonavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977935",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977935_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"ivacaftor\" outputclass=\"int-heading-drug\">Ivacaftor</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"rivaroxaban\" outputclass=\"int-drug\">rivaroxaban</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Ivacaftor   is predicted to   increase   the exposure to   rivaroxaban .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "58",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rivaroxaban</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977936",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977936_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"ivacaftor\" outputclass=\"int-heading-drug\">Ivacaftor</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"sirolimus\" outputclass=\"int-drug\">sirolimus</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Ivacaftor   is predicted to   increase   the exposure to   sirolimus .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "59",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sirolimus</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977937",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977937_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"St John's wort\" outputclass=\"int-drug\">St John's wort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ivacaftor\" outputclass=\"int-heading-drug\">ivacaftor</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "St John's wort   is predicted to   decrease   the exposure to   ivacaftor .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "60",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>St John's wort</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977938",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977938_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"ivacaftor\" outputclass=\"int-heading-drug\">Ivacaftor</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"tacrolimus\" outputclass=\"int-drug\">tacrolimus</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Ivacaftor   is predicted to   increase   the exposure to   tacrolimus .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "61",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tacrolimus</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977939",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977939_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"ivacaftor\" outputclass=\"int-heading-drug\">Ivacaftor</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-magnitude\">slightly</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"talazoparib\" outputclass=\"int-drug\">talazoparib</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid or adjust <ph otherprops=\"talazoparib\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/talazoparib.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP219854\">talazoparib</xref></ph> dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Ivacaftor   is predicted to   slightly   increase   the exposure to   talazoparib .  Manufacturer advises avoid or adjust  talazoparib  dose .    \n\n"
						}
					],
					"hasOrder": "62",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Talazoparib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977940",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977940_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Mild\" outputclass=\"int-message\">\n  <ph otherprops=\"ivacaftor\" outputclass=\"int-heading-drug\">Ivacaftor</ph> <ph outputclass=\"int-effectQualifier\">might</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"tigecycline\" outputclass=\"int-drug\">tigecycline</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Mild",
							"hasOrder": "1",
							"hasTextContent": "Ivacaftor   might   increase   the exposure to   tigecycline .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "63",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tigecycline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977941",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977941_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tipranavir\" outputclass=\"int-drug\">Tipranavir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ivacaftor\" outputclass=\"int-heading-drug\">ivacaftor</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust dose with potent CYP3A4 inhibitors, see <xref format=\"dita\" href=\"drug/ivacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP33421\">ivacaftor</xref>, <xref format=\"dita\" href=\"drug/lumacaftor-with-ivacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP202230\">lumacaftor with ivacaftor</xref>, <xref format=\"dita\" href=\"drug/tezacaftor-with-ivacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP218356\">tezacaftor with ivacaftor</xref>, and <xref format=\"dita\" href=\"drug/tezacaftor-with-ivacaftor-and-elexacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP221286\">tezacaftor with ivacaftor and elexacaftor</xref></ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tipranavir   is predicted to   increase   the exposure to   ivacaftor .  Manufacturer advises adjust dose with potent CYP3A4 inhibitors, see  ivacaftor ,  lumacaftor with ivacaftor ,  tezacaftor with ivacaftor , and  tezacaftor with ivacaftor and elexacaftor .    \n\n"
						}
					],
					"hasOrder": "64",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tipranavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977942",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977942_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"ivacaftor\" outputclass=\"int-heading-drug\">Ivacaftor</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"topotecan\" outputclass=\"int-drug\">topotecan</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Ivacaftor   is predicted to   increase   the exposure to   topotecan .  Manufacturer advises monitor .    \n\n"
						}
					],
					"hasOrder": "65",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Topotecan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977943",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977943_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"ivacaftor\" outputclass=\"int-heading-drug\">Ivacaftor</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"trametinib\" outputclass=\"int-drug\">trametinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Ivacaftor   is predicted to   increase   the concentration of   trametinib .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "66",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trametinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977944",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977944_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"ivacaftor\" outputclass=\"int-heading-drug\">Ivacaftor</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"venetoclax\" outputclass=\"int-drug\">venetoclax</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid or monitor for toxicity</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Ivacaftor   is predicted to   increase   the exposure to   venetoclax .  Manufacturer advises avoid or monitor for toxicity .    \n\n"
						}
					],
					"hasOrder": "67",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Venetoclax</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977945",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977945_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"verapamil\" outputclass=\"int-drug\">Verapamil</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ivacaftor\" outputclass=\"int-heading-drug\">ivacaftor</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust dose with moderate CYP3A4 inhibitors, see <xref format=\"dita\" href=\"drug/ivacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP33421\">ivacaftor</xref>, <xref format=\"dita\" href=\"drug/tezacaftor-with-ivacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP218356\">tezacaftor with ivacaftor</xref>, and <xref format=\"dita\" href=\"drug/tezacaftor-with-ivacaftor-and-elexacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP221286\">tezacaftor with ivacaftor and elexacaftor</xref></ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Verapamil   is predicted to   increase   the exposure to   ivacaftor .  Manufacturer advises adjust dose with moderate CYP3A4 inhibitors, see  ivacaftor ,  tezacaftor with ivacaftor , and  tezacaftor with ivacaftor and elexacaftor .    \n\n"
						}
					],
					"hasOrder": "68",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Verapamil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977946",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977946_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"ivacaftor\" outputclass=\"int-heading-drug\">Ivacaftor</ph> <ph outputclass=\"int-effectQualifier\">might</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"vinblastine\" outputclass=\"int-drug\">vinblastine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Ivacaftor   might   increase   the exposure to   vinblastine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "69",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vinblastine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977947",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977947_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"ivacaftor\" outputclass=\"int-heading-drug\">Ivacaftor</ph> <ph outputclass=\"int-effectQualifier\">might</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"vincristine\" outputclass=\"int-drug\">vincristine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Ivacaftor   might   increase   the exposure to   vincristine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "70",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vincristine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977948",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977948_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"ivacaftor\" outputclass=\"int-heading-drug\">Ivacaftor</ph> <ph outputclass=\"int-effectQualifier\">might</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"vindesine\" outputclass=\"int-drug\">vindesine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Ivacaftor   might   increase   the exposure to   vindesine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "71",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vindesine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977949",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977949_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"ivacaftor\" outputclass=\"int-heading-drug\">Ivacaftor</ph> <ph outputclass=\"int-effectQualifier\">might</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"vinflunine\" outputclass=\"int-drug\">vinflunine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Ivacaftor   might   increase   the exposure to   vinflunine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "72",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vinflunine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977950",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977950_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"ivacaftor\" outputclass=\"int-heading-drug\">Ivacaftor</ph> <ph outputclass=\"int-effectQualifier\">might</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"vinorelbine\" outputclass=\"int-drug\">vinorelbine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Ivacaftor   might   increase   the exposure to   vinorelbine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "73",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vinorelbine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977951",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977951_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"voriconazole\" outputclass=\"int-drug\">Voriconazole</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ivacaftor\" outputclass=\"int-heading-drug\">ivacaftor</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust dose with potent CYP3A4 inhibitors, see <xref format=\"dita\" href=\"drug/ivacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP33421\">ivacaftor</xref>, <xref format=\"dita\" href=\"drug/lumacaftor-with-ivacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP202230\">lumacaftor with ivacaftor</xref>, <xref format=\"dita\" href=\"drug/tezacaftor-with-ivacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP218356\">tezacaftor with ivacaftor</xref>, and <xref format=\"dita\" href=\"drug/tezacaftor-with-ivacaftor-and-elexacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP221286\">tezacaftor with ivacaftor and elexacaftor</xref></ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Voriconazole   is predicted to   increase   the exposure to   ivacaftor .  Manufacturer advises adjust dose with potent CYP3A4 inhibitors, see  ivacaftor ,  lumacaftor with ivacaftor ,  tezacaftor with ivacaftor , and  tezacaftor with ivacaftor and elexacaftor .    \n\n"
						}
					],
					"hasOrder": "74",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Voriconazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977952",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2#bnf_i1643857977952_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"ivacaftor\" outputclass=\"int-heading-drug\">Ivacaftor</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"warfarin\" outputclass=\"int-drug\">warfarin</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor INR</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Ivacaftor   is predicted to   increase   the exposure to   warfarin .  Manufacturer advises monitor INR .    \n\n"
						}
					],
					"hasOrder": "75",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Warfarin</title>"
					}
				}
			],
			"hasSearchLabel": " Ivacaftor  | Interactions",
			"hasSearchLink": {
				"@id": "http://bnf.nice.org.uk/interaction/ivacaftor-2.html"
			},
			"hasTitle": {
				"@type": "rdf:XMLLiteral",
				"@value": "<title> Ivacaftor </title>"
			},
			"rdfs:label": "ivacaftor"
		}
	]
}